Russell Investments Group Ltd. Sells 54,184 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Russell Investments Group Ltd. cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 18.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,791 shares of the medical instruments supplier's stock after selling 54,184 shares during the quarter. Russell Investments Group Ltd. owned 1.05% of LeMaitre Vascular worth $21,818,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LMAT. New York State Teachers Retirement System increased its stake in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock worth $755,000 after acquiring an additional 100 shares during the period. Flputnam Investment Management Co. lifted its position in LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock worth $269,000 after purchasing an additional 102 shares during the period. Norden Group LLC increased its holdings in LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after buying an additional 103 shares during the period. Blue Barn Wealth LLC lifted its holdings in shares of LeMaitre Vascular by 4.4% during the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock worth $229,000 after acquiring an additional 104 shares during the period. Finally, Shaker Investments LLC OH increased its stake in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after acquiring an additional 112 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on LMAT. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.25.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $0.12 during trading on Tuesday, reaching $83.67. The stock had a trading volume of 21,752 shares, compared to its average volume of 158,820. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58. The firm's fifty day moving average is $88.88 and its 200 day moving average is $93.68. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 45.68, a P/E/G ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.96%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.